AUTH:"Harper-Wynne C" - Search results

heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.

Kuemmel S, Harper-Wynne C, Park YH, Franke F, de Laurentiis M, Schumacher-Wulf E, Eiger D, Heeson S, Cardona A, Özyilkan Ö, Morales-Vàsquez F, Metcalfe C, Hafner M, Restuccia E, O'Shaughnessy J

BMC Cancer, 24(1):641, 24 May 2024

Cited by: 2 articles | PMID: 38789924 | PMCID: PMC11127459

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer.

Coakley M, Villacampa G, Sritharan P, Swift C, Dunne K, Kilburn L, Goddard K, Pipinikas C, Rojas P, Emmett W, Hall P, Harper-Wynne C, Hickish T, Macpherson I, Okines A, Wardley A, Wheatley D, Waters S, Palmieri C, [...] Turner NC

Clin Cancer Res, 30(4):895-903, 01 Feb 2024

Cited by: 4 articles | PMID: 38078899 | PMCID: PMC10870111

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Resistance patterns in drug-adapted cancer cell lines reflect the complex evolution in clinical tumours

Grimsley HE, Antczak M, Reddin IG, McLaughlin K, Nist A, Mernberger M, Stiewe T, Fenton TR, Speidel D, Harper-Wynne C, Cox K, Cinatl J, Wass MN, Garrett MD, Michaelis M

bioRxiv, 23 Jan 2024

Cited by: 0 articles | PPR: PPR791954

Add to export list Preprint

A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP).

Starkey T, Ionescu MC, Tilby M, Little M, Burke E, Fittall MW, Khan S, Liu JKH, Platt JR, Mew R, Tripathy AR, Watts I, Williams ST, Appanna N, Al-Hajji Y, Barnard M, Benny L, Burnett A, Bytyci J, [...] Lee LYW

Sci Rep, 13(1):11327, 25 Jul 2023

Cited by: 4 articles | PMID: 37491478 | PMCID: PMC10368624

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program.

Palmieri C, Musson A, Harper-Wynne C, Wheatley D, Bertelli G, Macpherson IR, Nathan M, McDowall E, Bhojwani A, Verrill M, Eva J, Doody C, Chowdhury R

Br J Cancer, 129(5):852-860, 19 Jul 2023

Cited by: 2 articles | PMID: 37468569 | PMCID: PMC10449843

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation.

Lee LYW, Tilby M, Starkey T, Ionescu MC, Burnett A, Hattersley R, Khan S, Little M, Liu JKH, Platt JR, Tripathy A, Watts I, Williams ST, Appanna N, Al-Hajji Y, Barnard M, Benny L, Buckley A, Cattell E, [...] UK COVID Cancer Programme

JAMA Oncol, 9(2):188-196, 01 Feb 2023

Cited by: 15 articles | PMID: 36547970 | PMCID: PMC9936347

Add to export list Free full text in Europe PMC

Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.

Turner NC, Swift C, Jenkins B, Kilburn L, Coakley M, Beaney M, Fox L, Goddard K, Garcia-Murillas I, Proszek P, Hall P, Harper-Wynne C, Hickish T, Kernaghan S, Macpherson IR, Okines AFC, Palmieri C, Perry S, Randle K, [...] c-TRAK TN investigators

Ann Oncol, 34(2):200-211, 22 Nov 2022

Cited by: 42 articles | PMID: 36423745

Add to export list

Safe prescribing in cancer patients during the COVID-19 pandemic: A new initiative from the UK Cancer Coronavirus Project (UKCCP) team.

Appanna N, Patel G, Burke E, Burnett A, Clark J, Mew R, Khan S, Little M, Liu J, Panneerselvam H, Patel V, Platt J, Tilby M, Watts I, Harper-Wynne C, Lee LYW

Int J Cancer, 152(6):1275-1277, 08 Dec 2022

Cited by: 0 articles | PMID: 36454180 | PMCID: PMC9877804

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study.

Lee LYW, Ionescu MC, Starkey T, Little M, Tilby M, Tripathy AR, Mckenzie HS, Al-Hajji Y, Appanna N, Barnard M, Benny L, Burnett A, Cattell EL, Clark JJ, Khan S, Ghafoor Q, Panneerselvam H, Illsley G, Harper-Wynne C, [...] UK Coronavirus Cancer Programme

Eur J Cancer, 175:1-10, 13 Jul 2022

Cited by: 25 articles | PMID: 36084618 | PMCID: PMC9276646

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study.

Lee LYW, Starkey T, Ionescu MC, Little M, Tilby M, Tripathy AR, Mckenzie HS, Al-Hajji Y, Barnard M, Benny L, Burnett A, Cattell EL, Charman J, Clark JJ, Khan S, Ghafoor Q, Illsley G, Harper-Wynne C, Hattersley RJ, [...] Johnson P

Lancet Oncol, 23(6):748-757, 23 May 2022

Cited by: 54 articles | PMID: 35617989 | PMCID: PMC9126559

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, [...] KEYNOTE-522 Investigators

N Engl J Med, 386(6):556-567, 01 Feb 2022

Cited by: 363 articles | PMID: 35139274

Add to export list

Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: Challenges and lessons learnt from comparison of the UK and Australian experience.

Porter I, Theodoulou E, Holen I, Harper-Wynne C, Baron-Hay S, Wilson C, Brown J

J Bone Oncol, 31:100402, 01 Nov 2021

Cited by: 5 articles | PMID: 34804788 | PMCID: PMC8581365

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study.

El Badri S, Tahir B, Balachandran K, Bezecny P, Britton F, Davies M, Desouza K, Dixon S, Hills D, Moe M, Pigott T, Proctor A, Shah Y, Simcock R, Stansfeld A, Synowiec A, Theodoulou M, Verrill M, Wadhawan A, [...] Wilson C

Breast, 60:199-205, 28 Oct 2021

Cited by: 12 articles | PMID: 34736090 | PMCID: PMC8569699

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Enhanced axillary assessment using intradermally injected microbubbles and contrast-enhanced ultrasound (CEUS) before neoadjuvant systemic therapy (NACT) identifies axillary disease missed by conventional B-mode ultrasound that may be clinically relevant.

Cox K, Dineen N, Taylor-Phillips S, Sharma N, Harper-Wynne C, Allen D, Weeks J, Chalmers R, Akolekar D, Burcombe R, Jyothirmayi R, Sever A

Breast Cancer Res Treat, 185(2):413-422, 07 Oct 2020

Cited by: 3 articles | PMID: 33029707

Add to export list

The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.

Crolley VE, Marashi H, Rawther S, Sirohi B, Parton M, Graham J, Vinayan A, Sutherland S, Rigg A, Wadhawan A, Harper-Wynne C, Spurrell E, Bond H, Raja F, King J

Breast Cancer Res Treat, 180(3):809-817, 13 Mar 2020

Cited by: 20 articles | PMID: 32170635 | PMCID: PMC7103011

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Pembrolizumab for Early Triple-Negative Breast Cancer.

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, [...] KEYNOTE-522 Investigators

N Engl J Med, 382(9):810-821, 01 Feb 2020

Cited by: 1112 articles | PMID: 32101663

Add to export list

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial.

Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G, Brunt AM, Kuemmel S, Ruiz I, Perelló A, Kendall A, Brown J, Kristeleit H, Conibear J, Saura C, Grenier J, Máhr K, [...] Cortés J

JAMA Oncol, 5(11):1556-1564, 01 Nov 2019

Cited by: 48 articles | PMID: 31465093 | PMCID: PMC6865233

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.

Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, [...] PERSEPHONE Steering Committee and Trial Investigators

Lancet, 393(10191):2599-2612, 06 Jun 2019

Cited by: 128 articles | PMID: 31178152 | PMCID: PMC6615016

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Bronchoalveolar carcinoma as an unsuspected cause for worsening shortness of breath in a patient with metastatic breast cancer.

Nagpal SK, Flynn M, Ryan C, Harper-Wynne C

BMJ Case Rep, 2018:bcr-2018-226125, 08 Nov 2018

Cited by: 0 articles | PMID: 30413446 | PMCID: PMC6229094

Add to export list Free full text in Europe PMC

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, [...] Bliss JM

Nat Med, 24(5):628-637, 30 Apr 2018

Cited by: 417 articles | PMID: 29713086 | PMCID: PMC6372067

Add to export list Free full text in Europe PMC

Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).

Leary A, Evans A, Johnston SR, A'Hern R, Bliss JM, Sahoo R, Detre S, Haynes BP, Hills M, Harper-Wynne C, Bundred N, Coombes G, Smith I, Dowsett M

Clin Cancer Res, 21(13):2932-2940, 14 Nov 2014

Cited by: 17 articles | PMID: 25398453

Add to export list

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.

Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, Abraham J, Thomas J, Provenzano E, Hughes-Davies L, Gounaris I, McAdam K, Chan S, Ahmad R, Hickish T, Houston S, Rea D, Bartlett J, Caldas C, [...] ARTemis Investigators

Lancet Oncol, 16(6):656-666, 11 May 2015

Cited by: 82 articles | PMID: 25975632

Add to export list

Febrile neutropaenia and chemotherapy discontinuation in women aged 70 years or older receiving adjuvant chemotherapy for early breast cancer.

Adjogatse D, Thanopoulou E, Okines A, Thillai K, Tasker F, Johnston SR, Harper-Wynne C, Torrisi E, Ring A

Clin Oncol (R Coll Radiol), 26(11):692-696, 06 Jun 2014

Cited by: 9 articles | PMID: 24909701

Add to export list

Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk.

Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, Whiffin N, Tenesa A, Spain S, Broderick P, Ooi LY, Domingo E, Smillie C, Henrion M, Frampton M, Martin L, Grimes G, Gorman M, Semple C, Ma YP, [...] Houlston RS

Nat Genet, 44(7):770-776, 27 May 2012

Cited by: 175 articles | PMID: 22634755 | PMCID: PMC4747430

Add to export list Free full text in Europe PMC

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.

Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, Turnbull C, Houlston R, Shanley S, Butler S, Evans DG, Ross G, Eccles D, Tutt A, Rahman N, TNT Trial TMG, BCSC (UK)

Br J Cancer, 106(6):1234-1238, 14 Feb 2012

Cited by: 66 articles | PMID: 22333603 | PMCID: PMC3304410

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer.

Resistance patterns in drug-adapted cancer cell lines reflect the complex evolution in clinical tumours

A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP).

A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program.

Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation.

Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.

Safe prescribing in cancer patients during the COVID-19 pandemic: A new initiative from the UK Cancer Coronavirus Project (UKCCP) team.

COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study.

Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study.

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.

Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: Challenges and lessons learnt from comparison of the UK and Australian experience.

Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study.

Enhanced axillary assessment using intradermally injected microbubbles and contrast-enhanced ultrasound (CEUS) before neoadjuvant systemic therapy (NACT) identifies axillary disease missed by conventional B-mode ultrasound that may be clinically relevant.

The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.

Pembrolizumab for Early Triple-Negative Breast Cancer.

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial.

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.

Bronchoalveolar carcinoma as an unsuspected cause for worsening shortness of breath in a patient with metastatic breast cancer.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.

Febrile neutropaenia and chemotherapy discontinuation in women aged 70 years or older receiving adjuvant chemotherapy for early breast cancer.

Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk.

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.

Partnerships & funding